Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 19, Number 3—March 2013

Research

Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009–2010

Rebekah H. Borse1, Sundar S. Shrestha, Anthony E. Fiore, Charisma Y. Atkins, James A. Singleton, Carolyn Furlow, and Martin I. MeltzerComments to Author 
Author affiliations: Author affiliation: Centers for Disease Control and Prevention, Atlanta, Georgia, USA

Main Article

Table 10

Results of sensitivity analyses to determine effects of assumed percentages of subclinical cases of influenza A(H1N1)pdm09 virus infection*

Assumed proportion subclinical cases No. clinical cases prevented (range)
50% 891,682 (651,567–1,135,546)
30% (base estimate) 1,029,157 (712,908–1,458,930)
0% 1,133,734 (759,341–1,706,714)

*Data reflect calculations made for scenario 8 by changing assumed percentages of subclinical cases of influenza.

Main Article

1Current affiliation: Merck & Co., Inc., Lansdale, Pennsylvania, USA.

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO